OCA at 05:43, 7 June 2023

OCA — Wed, 07 Jun 2023 05:43:57 GMT

←Older revision		Revision as of 05:43, 7 June 2023
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 8sk4 is ~~ON HOLD~~	+	==Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors)==
		+	<StructureSection load='8sk4' size='340' side='right'caption='[[8sk4]], [[Resolution\|resolution]] 2.00Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[8sk4]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome_coronavirus_2 Severe acute respiratory syndrome coronavirus 2]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8SK4 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8SK4 FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=I3R:2-chloro-1-[(5R)-3-phenyl-5-(quinoxalin-5-yl)-4,5-dihydro-1H-pyrazol-1-yl]ethan-1-one'>I3R</scene>, <scene name='pdbligand=IMD:IMIDAZOLE'>IMD</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8sk4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8sk4 OCA], [https://pdbe.org/8sk4 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8sk4 RCSB], [https://www.ebi.ac.uk/pdbsum/8sk4 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8sk4 ProSAT]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/R1AB_SARS2 R1AB_SARS2] Multifunctional protein involved in the transcription and replication of viral RNAs. Contains the proteinases responsible for the cleavages of the polyprotein.[UniProtKB:P0C6X7] Inhibits host translation by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome complex further induces an endonucleolytic cleavage near the 5'UTR of host mRNAs, targeting them for degradation. Viral mRNAs are not susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the presence of a 5'-end leader sequence and are therefore protected from degradation. By suppressing host gene expression, nsp1 facilitates efficient viral gene expression in infected cells and evasion from host immune response.[UniProtKB:P0C6X7] May play a role in the modulation of host cell survival signaling pathway by interacting with host PHB and PHB2. Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses.[UniProtKB:P0C6X7] Responsible for the cleavages located at the N-terminus of the replicase polyprotein. In addition, PL-PRO possesses a deubiquitinating/deISGylating activity and processes both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular substrates. Participates together with nsp4 in the assembly of virally-induced cytoplasmic double-membrane vesicles necessary for viral replication. Antagonizes innate immune induction of type I interferon by blocking the phosphorylation, dimerization and subsequent nuclear translocation of host IRF3. Prevents also host NF-kappa-B signaling.[UniProtKB:P0C6X7] Participates in the assembly of virally-induced cytoplasmic double-membrane vesicles necessary for viral replication.[UniProtKB:P0C6X7] Cleaves the C-terminus of replicase polyprotein at 11 sites. Recognizes substrates containing the core sequence [ILMVF]-Q-\|-[SGACN] (PubMed:32198291). Also able to bind an ADP-ribose-1''-phosphate (ADRP).[UniProtKB:P0C6X7]<ref>PMID:32198291</ref> Plays a role in the initial induction of autophagosomes from host reticulum endoplasmic. Later, limits the expansion of these phagosomes that are no longer able to deliver viral components to lysosomes.[UniProtKB:P0C6X7] Forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers.[UniProtKB:P0C6X7] Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers.[UniProtKB:P0C6X7] May participate in viral replication by acting as a ssRNA-binding protein.[UniProtKB:P0C6X7] Plays a pivotal role in viral transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16 2'-O-methyltransferase activities. Therefore plays an essential role in viral mRNAs cap methylation.[UniProtKB:P0C6X7] Responsible for replication and transcription of the viral RNA genome.[UniProtKB:P0C6X7] Multi-functional protein with a zinc-binding domain in N-terminus displaying RNA and DNA duplex-unwinding activities with 5' to 3' polarity. Activity of helicase is dependent on magnesium.[UniProtKB:P0C6X7] Enzyme possessing two different activities: an exoribonuclease activity acting on both ssRNA and dsRNA in a 3' to 5' direction and a N7-guanine methyltransferase activity. Acts as a proofreading exoribonuclease for RNA replication, thereby lowering The sensitivity of the virus to RNA mutagens.[UniProtKB:P0C6X7] Mn(2+)-dependent, uridylate-specific enzyme, which leaves 2'-3'-cyclic phosphates 5' to the cleaved bond.[UniProtKB:P0C6X7] Methyltransferase that mediates mRNA cap 2'-O-ribose methylation to the 5'-cap structure of viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of nsp16. Therefore plays an essential role in viral mRNAs cap methylation which is essential to evade immune system.[UniProtKB:P0C6X7]
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	While vaccines and antivirals are now being deployed for the current SARS-CoV-2 pandemic, we require additional antiviral therapeutics to not only effectively combat SARS-CoV-2 and its variants, but also future coronaviruses. All coronaviruses have relatively similar genomes that provide a potential exploitable opening to develop antiviral therapies that will be effective against all coronaviruses. Among the various genes and proteins encoded by all coronaviruses, one particularly "druggable" or relatively easy-to-drug target is the coronavirus Main Protease (3CL(pro) or Mpro), an enzyme that is involved in cleaving a long peptide translated by the viral genome into its individual protein components that are then assembled into the virus to enable viral replication in the cell. Inhibiting Mpro with a small-molecule antiviral would effectively stop the ability of the virus to replicate, providing therapeutic benefit. In this study, we have utilized activity-based protein profiling (ABPP)-based chemoproteomic approaches to discover and further optimize cysteine-reactive pyrazoline-based covalent inhibitors for the SARS-CoV-2 Mpro. Structure-guided medicinal chemistry and modular synthesis of di- and tri-substituted pyrazolines bearing either chloroacetamide or vinyl sulfonamide cysteine-reactive warheads enabled the expedient exploration of structure-activity relationships (SAR), yielding nanomolar potency inhibitors against Mpro from not only SARS-CoV-2, but across many other coronaviruses. Our studies highlight promising chemical scaffolds that may contribute to future pan-coronavirus inhibitors.

-	~~Authors:~~ Knapp, M.S., ~~Ornelas, E~~.	+	Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors.,Moon P, Zammit CM, Shao Q, Dovala D, Boike L, Henning NJ, Knapp M, Spradlin JN, Ward CC, Wolleb H, Fuller D, Blake G, Murphy JP, Wang F, Lu Y, Moquin SA, Tandeske L, Hesse MJ, McKenna JM, Tallarico JA, Schirle M, Toste FD, Nomura DK Chembiochem. 2023 Jun 1;24(11):e202300116. doi: 10.1002/cbic.202300116. Epub 2023 , May 3. PMID:37069799<ref>PMID:37069799</ref>

-	~~Description: Co-structure~~ of ~~SARS~~-~~CoV~~-~~2 (COVID-19 with covalent pyrazoline based inhibitors)~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased~~ Structures]]	+	</div>
-	[[Category: Knapp~~, M.S~~]]	+	<div class="pdbe-citations 8sk4" style="background-color:#fffaf0;"></div>
-	[[Category: Ornelas, E]]	+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Large Structures]]
		+	[[Category: Severe acute respiratory syndrome coronavirus 2]]
		+	[[Category: Knapp MS]]
		+	[[Category: Ornelas E]]

OCA at 05:20, 10 May 2023

OCA — Wed, 10 May 2023 05:20:36 GMT

←Older revision		Revision as of 05:20, 10 May 2023
Line 5:		Line 5:
	Authors: Knapp, M.S., Ornelas, E.		Authors: Knapp, M.S., Ornelas, E.

-	Description: Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors	+	Description: Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors)
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
-	[[Category: Ornelas, E]]
	[[Category: Knapp, M.S]]		[[Category: Knapp, M.S]]
		+	[[Category: Ornelas, E]]

OCA: Protected "8sk4" [edit=sysop:move=sysop]

OCA — Wed, 26 Apr 2023 15:28:26 GMT

Protected "8sk4" [edit=sysop:move=sysop]

←Older revision

Revision as of 15:28, 26 April 2023

OCA: New page: '''Unreleased structure''' The entry 8sk4 is ON HOLD Authors: Knapp, M.S., Ornelas, E. Description: Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors [[Cat...

OCA — Wed, 26 Apr 2023 15:28:25 GMT

New page: '''Unreleased structure''' The entry 8sk4 is ON HOLD Authors: Knapp, M.S., Ornelas, E. Description: Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors [[Cat...

New page

'''Unreleased structure'''

The entry 8sk4 is ON HOLD

Authors: Knapp, M.S., Ornelas, E.

Description: Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors
[[Category: Unreleased Structures]]
[[Category: Ornelas, E]]
[[Category: Knapp, M.S]]

8sk4 - Revision history

OCA at 05:43, 7 June 2023

OCA at 05:20, 10 May 2023

OCA: Protected "8sk4" [edit=sysop:move=sysop]

OCA: New page: '''Unreleased structure''' The entry 8sk4 is ON HOLD Authors: Knapp, M.S., Ornelas, E. Description: Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors [[Cat...